Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.

Lewis Rubinson, Alfred Corey, Dan Hanfling
{"title":"Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.","authors":"Lewis Rubinson,&nbsp;Alfred Corey,&nbsp;Dan Hanfling","doi":"10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an anti-PA monoclonal antibody, has been approved for therapeutic use using the Animal Rule. Given the paucity of human inhalational anthrax clinical data including PA kinetics, the post-exposure period for effective treatment of human disease remains unknown. The objective of this investigation was to extrapolate animal PA kinetics to a conceptual human model to estimate the post-exposure period for effective treatment of human inhalational anthrax.</p><p><strong>Methods: </strong>Human PA kinetic parameters were extrapolated from reported rabbit and monkey data. PA profiles were simulated with and without antibiotic induced PA clearance to represent antibiotic-sensitive and -resistant infections, respectively. Antitoxin levels equimolar to or greater than concurrent PA levels were considered protective.</p><p><strong>Results: </strong>For antibiotic sensitive infections, treatment with antibiotics alone ≤4 days after spore exposure prevents toxemia. Administration of raxibacumab together with antibiotics protects ≥ 80% of subjects for 3 additional days (7 days post exposure). In the setting of antibiotic resistance, raxibacumab would be protective for at least 6 days post exposure.</p><p><strong>Conclusions: </strong>Although the animal model of disease does not reflect the potential impact of supportive care (e.g. fluid resuscitation received by critically ill patients) on PA kinetics and raxibacumab PK, the simulations suggest that administration of antitoxin in combination with antibiotics should provide a longer postexposure window for effective treatment than for antibiotics alone. In addition, raxibacumab administration soon after exposure to an antibiotic resistant strain should provide effective treatment.</p>","PeriodicalId":74464,"journal":{"name":"PLoS currents","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555766/pdf/","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS currents","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Introduction: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the mortality, and raxibacumab, an anti-PA monoclonal antibody, has been approved for therapeutic use using the Animal Rule. Given the paucity of human inhalational anthrax clinical data including PA kinetics, the post-exposure period for effective treatment of human disease remains unknown. The objective of this investigation was to extrapolate animal PA kinetics to a conceptual human model to estimate the post-exposure period for effective treatment of human inhalational anthrax.

Methods: Human PA kinetic parameters were extrapolated from reported rabbit and monkey data. PA profiles were simulated with and without antibiotic induced PA clearance to represent antibiotic-sensitive and -resistant infections, respectively. Antitoxin levels equimolar to or greater than concurrent PA levels were considered protective.

Results: For antibiotic sensitive infections, treatment with antibiotics alone ≤4 days after spore exposure prevents toxemia. Administration of raxibacumab together with antibiotics protects ≥ 80% of subjects for 3 additional days (7 days post exposure). In the setting of antibiotic resistance, raxibacumab would be protective for at least 6 days post exposure.

Conclusions: Although the animal model of disease does not reflect the potential impact of supportive care (e.g. fluid resuscitation received by critically ill patients) on PA kinetics and raxibacumab PK, the simulations suggest that administration of antitoxin in combination with antibiotics should provide a longer postexposure window for effective treatment than for antibiotics alone. In addition, raxibacumab administration soon after exposure to an antibiotic resistant strain should provide effective treatment.

Abstract Image

Abstract Image

Abstract Image

估计人类吸入性炭疽有效治疗包括抗毒素治疗的时间。
罕见的自然人类吸入性炭疽病例加上较高的生物恐怖主义风险,使得使用动物模型作为批准新治疗方法的基础。对于吸入性炭疽,保护性抗原(PA)导致了大部分死亡率,而抗PA单克隆抗体瑞希巴库(rxibacumab)已根据动物规则被批准用于治疗。由于缺乏人类吸入性炭疽临床数据,包括PA动力学,暴露后有效治疗人类疾病的时间仍然未知。本研究的目的是将动物PA动力学外推到一个概念性人类模型,以估计有效治疗人类吸入性炭疽的暴露后时间。方法:根据兔和猴的报告数据推断人体PA动力学参数。分别模拟有和没有抗生素诱导的PA清除的PA谱,以代表抗生素敏感和耐药感染。抗毒素水平等于或大于同时的PA水平被认为具有保护作用。结果:对于抗生素敏感感染,孢子暴露后≤4天单独使用抗生素可预防毒血症。瑞希巴库与抗生素联合用药可保护≥80%的受试者3天(暴露后7天)。在抗生素耐药的情况下,雷希巴库在暴露后至少6天内具有保护作用。结论:尽管动物疾病模型并没有反映支持治疗(如危重患者接受的液体复苏)对PA动力学和瑞希巴库PK的潜在影响,但模拟表明,抗毒素与抗生素联合使用应该比单独使用抗生素提供更长的暴露后有效治疗窗口。此外,暴露于抗生素耐药菌株后不久给予雷希巴库应提供有效的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信